Literature DB >> 10143700

A note on the depreciation of the societal perspective in economic evaluation of health care.

M Johannesson1.   

Abstract

It is common in cost-effectiveness analyses of health care to only include health care costs, with the argument that some fictive 'health care budget' should be used to maximize the health effects. This paper provides a criticism of the 'health care budget' approach to cost-effectiveness analysis of health care. It is argued that the approach is ad hoc and lacks theoretical foundation. The approach is also inconsistent with using a fixed budget as the decision rule for cost-effectiveness analysis. That is the case unless only costs that fall into a single annual actual budget are included in the analysis, which would mean that any cost paid by the patients should be excluded as well as any future cost changes and all costs that fall on other budgets. Furthermore the prices facing the budget holder should be used, rather than opportunity costs. It is concluded that the 'health care budget' perspective should be abandoned and the societal perspective reinstated in economic evaluation of health care.

Entities:  

Mesh:

Year:  1995        PMID: 10143700     DOI: 10.1016/0168-8510(94)00677-7

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  10 in total

Review 1.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

Review 2.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 3.  Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions.

Authors:  Sanjoy Roy; S Suresh Madhavan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Perspectives in economic evaluation.

Authors:  S Byford; J Raftery
Journal:  BMJ       Date:  1998-05-16

Review 5.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

6.  Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage.

Authors:  Grace Lim; Vladyslav Melnyk; Francesca L Facco; Jonathan H Waters; Kenneth J Smith
Journal:  Anesthesiology       Date:  2018-02       Impact factor: 7.892

Review 7.  A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.

Authors:  Marieke Krol; Jocé Papenburg; Siok Swan Tan; Werner Brouwer; Leona Hakkaart
Journal:  Eur J Health Econ       Date:  2015-04-16

8.  Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions.

Authors:  Helen Dakin; Alastair Gray
Journal:  Med Decis Making       Date:  2018-05       Impact factor: 2.583

Review 9.  Cost effectiveness of HIV and sexual reproductive health interventions targeting sex workers: a systematic review.

Authors:  Giulia Rinaldi; Hassan Haghparast-Bidgoli; Aliasghar A Kiadaliri
Journal:  Cost Eff Resour Alloc       Date:  2018-12-04

10.  In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era.

Authors:  Werner Brouwer; Samare Huls; Ayesha Sajjad; Tim Kanters; Leona Hakkaart-van Roijen; Job van Exel
Journal:  Pharmacoeconomics       Date:  2021-12-16       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.